Eichenfield LF, McFalda W, Brabec B, et al. - In 2 identical phase 3 trials (Cantharidin Application in Molluscum Patients [CAMP-1 and CAMP-2]), researchers sought to determine the safety and effectiveness of VP-102, a drug-device combination containing cantharidin, 0.7% (w/v), compared with vehicle in individuals with molluscum contagiosum (MC). Study participants were randomized (3:2) to topical application of VP-102 or vehicle to all treatable lesions every 21 days before full clearance of the lesion or up to 4 treatments. Of the 528 candidates recruited, 527 received treatment (CAMP-1, n = 265; CAMP-2, n = 262). In achieving full clearance of MC lesions at the end of the study visit, VP-102 was statistically significantly superior to the vehicle in both studies, with adverse events that were usually mild to moderate and limited to application sites. Such results indicate that VP-102 is a potentially effective and safe treatment for MC, a common skin condition with no US Food and Drug Administration–approved treatments.